Home Blog Page 672

Christie’s and Porsche Design Tower Bangkok Host an Exclusive Collector’s Evening in Bangkok


STUTTGART, GERMANY / BANGKOK, THAILAND – Media OutReach Newswire – 29 April 2026 -Porsche Design Tower Bangkok and Christie’s co-hosted The Collector’s Evening, an exclusive invitation-only event held at The Peak, Gaysorn Tower, Bangkok. The private gathering brought together rare highlights from Christie’s forthcoming Hong Kong and Geneva auctions before a distinguished audience of collectors, investors, and wealth intermediaries, marking one of the most distinguished gatherings of collectors Bangkok has seen this year.

Melissa Chollasap (4th from left), Managing Director of Porsche Design Tower Bangkok, and Prapavadee Sophonpanich (5th from left), Senior Vice President, Managing Director of Christie's Thailand, Cambodia, Laos, Myanmar and Vietnam, co-hosted The Collector's Evening, a private preview of rare highlights from Christie's forthcoming Hong Kong and Geneva auctions, in Bangkok.
Melissa Chollasap (4th from left), Managing Director of Porsche Design Tower Bangkok, and Prapavadee Sophonpanich (5th from left), Senior Vice President, Managing Director of Christie’s Thailand, Cambodia, Laos, Myanmar and Vietnam, co-hosted The Collector’s Evening, a private preview of rare highlights from Christie’s forthcoming Hong Kong and Geneva auctions, in Bangkok.

The auction preview brought together a rare timepiece, a significant work of jewelry art, and a highly limited collectible — each with a provenance and a place in the collector market that extends well beyond its auction estimate. The evening was led by Vickie Sek, Deputy Chairman and Asia Pacific Chairman of Christie’s, and Alexandre Bigler, Senior Vice President and Head of Watches for Asia Pacific, whose attendance of the event in Bangkok reflects the growing weight of the city’s collector community on the regional stage. This year marks Christie’s 40th year of presence in Asia.

Porsche Design Tower Bangkok served as co-host — an adequate setting that reflects the exclusivity of the objects on display. Born from the collaboration between Porsche Design and Ananda Development PCL, the tower is guided by Professor F. A. Porsche’s founding principle of optimising function while uncompromisingly reducing form to the essentials. The result is ‘Sky Villa’ residences — distinguished by design, exclusive in the truest sense, and coveted by those who understand the true meaning and value of architectural excellence. With just 22 residences, Porsche Design Tower Bangkok underscores its profound exclusivity but unequivocally establishes it as an unparalleled, coveted address. Beyond the preview, the evening served as an intimate occasion for Porsche Design Tower Bangkok to host its clients and prospective owners within a setting that reflected the project’s own collector values.

Central to that distinction is the ‘Passion Space’ — a private collector’s garage directly connected to each residence by private lift. Whatever its owner chooses to place within it, the ‘Passion Space’ was designed with the same conviction that defined the evening: that what individuals surround themselves with is never incidental.

Porsche Design Tower Bangkok emerges as one of merely two Porsche Design residential towers globally, drawing a parallel only with its prestigious Miami counterpart.

For those who value the extraordinary, Porsche Design Tower Bangkok welcomes private viewings by appointment at pdtowerbangkok.com.

Hashtag: #PorscheDesign

The issuer is solely responsible for the content of this announcement.

About Porsche Design:

In 1963, Professor Ferdinand Alexander Porsche created one of the most iconic design objects in contemporary history: the Porsche 911. Following his vision to take the principles and myth of Porsche beyond the automotive world, he created the exclusive lifestyle brand Porsche Design in 1972. His philosophy and design language can still be seen in all Porsche Design products today. Every Porsche Design product stands for extraordinary precision and perfection, boasts a high level of technological innovation and seamlessly combines intelligent functionality and puristic design. Created by Studio F. A. Porsche in Austria, our products are sold worldwide in Porsche Design stores, high-end department stores, exclusive specialist retailers and the official online store ().

European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe

SHANGHAI, April 29, 2026 /PRNewswire/ — Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.[1]

“As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly  as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.[2],[3]  “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of health care systems while advancing women’s health through access to quality medicines.”[3],[4]

“Building on POHERDY’s FDA approval in the United States as the country’s first pertuzumab biosimilar, this EU approval further expands our growing portfolio of approved biosimilar medicines in markets around the world and is a testament to our strong collaboration with Organon,” said Ping Cao, Chief Business Development Officer and Senior Vice President of Henlius. “Guided by our commitment to scientific excellence and product quality, we are working to expand access to additional treatment options for the benefit of patients and the health care system.”

In Europe, POHERDY is indicated in combination with trastuzumab and docetaxel for the treatment of adults with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for metastatic disease. POHERDY is also indicated for use in combination with trastuzumab and chemotherapy as (i) neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence and (ii) adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence.

POHERDY was approved based on the review of a comprehensive data package, which included structural and functional analytical data, clinical pharmacokinetic data, and comparative clinical studies demonstrating that POHERDY is a biological medicine highly similar to the reference product based on a totality of evidence, including analytical, pharmacokinetic, efficacy, safety, and immunogenicity data  (the intrinsic ability of proteins and other biological medicines to cause an immune response).[5]

In 2022, Henlius entered into a license and supply agreement with Organon, granting Organon the exclusive commercialization rights to several biosimilars, including POHERDY. The agreement covers exclusive global commercialization rights except for China.[6]

About POHERDY® (pertuzumab) in the E.U.

Early breast cancer 
POHERDY is indicated for use in combination with trastuzumab and chemotherapy in:

  • the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence
  • the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence (see section 5.1)

Metastatic breast cancer 
POHERDY is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

For more information please visit: Poherdy | European Medicines Agency (EMA)

About Henlius

Shanghai Henlius Biotech, Inc. (2696.HK) is a global, innovation-driven biopharmaceutical company committed to delivering high-quality, affordable biologic therapies to patients worldwide. The Company focuses on major disease areas including oncology, autoimmune diseases, and ophthalmic diseases. Founded in 2010, Henlius has established an integrated, end-to-end biopharmaceutical platform encompassing global R&D, clinical operations, regulatory affairs, manufacturing, and commercialisation. The Company employs nearly 4,000 people globally and operates across multiple regions, including China, the United States, and Japan. Leveraging the stable cash flow generated from its biosimilar portfolio to support innovation, Henlius is steadily advancing into its “Globalisation 2.0” phase, building a scalable and sustainable global growth model. As of early 2026, Henlius has achieved regulatory approvals for 10 products across over 60 countries and regions worldwide, including seven approvals in China. The Company has also reached multiple milestones in major biopharmaceutical markets, with four products approved by the U.S. Food and Drug Administration (FDA) and five products approved by the European Commission (EC), reflecting its globally aligned R&D capabilities, quality systems, and manufacturing standards.

Driven by innovation, Henlius has built a diversified, platform-based technology ecosystem through coordinated R&D efforts across Shanghai, the United States, and other regions. Its innovation platforms span immune checkpoint inhibitors, immune cell engager technologies (including multispecific T cell engagers), antibody-drug conjugates (ADCs), and AI-enabled early discovery platforms. The Company currently has more than 50 early-stage innovative assets, approximately 70% of which are expected to be best-in-class, with over 30 clinical trials ongoing globally. Henlius’ core product, serplulimab (trade name: Hetronifly® in Europe), is the world’s first anti–PD-1 mAb approved for first-line treatment of small cell lung cancer and has been approved in more than 40 markets worldwide with an accelerated globalisation process. In parallel, multiple high-potential innovative assets—including the PD-L1 ADC HLX43 and the novel epitope anti-HER2 mAb HLX22—are advancing through global pivotal clinical development. Supported by a biologics manufacturing network with a total capacity of 84,000L and GMP certifications from regulatory authorities in China, Europe, and the United States, Henlius has established a stable global supply system serving six continents. Guided by a patient-centred mission, Henlius remains focused on addressing unmet medical needs and translating scientific innovation into meaningful clinical value and patient access, contributing sustainably to the global biopharmaceutical ecosystem.

To learn more about Henlius, visit https://www.henlius.com/en/index.html and connect with us on LinkedIn at https://www.linkedin.com/company/henlius/.

About Organon

Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets. 

Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at www.organon.com and follow us on LinkedIn, Instagram, X, YouTube, TikTok and Facebook.

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about POHERDY treatment goals and Organon’s ongoing commitment to supporting the sustainability of health care systems while advancing women’s health through access to quality medicine. Forward-looking statements may be identified by words such as “will,” “plan,” “ongoing,” “commitment to supporting,” “may,” and words of similar meaning. These statements are based upon the current beliefs and expectations of Organon’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon’s filings with the SEC, including Organon’s most recent Annual Report on Form 10-K and other SEC filings, available at the SEC’s Internet site (www.sec.gov). Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

PERJETA is a trademark registered in the European Union by F. Hoffmann-La Roche AG; Organon is not associated with this trademark owner.

1. PERJETA. Product Information. Genentech, Inc.; 2025.

2. Breast cancer in the EU. European Commission, Joint Research Centre. October 2023. Accessed April 14, 2026.
    https://ecis.jrc.ec.europa.eu/sites/default/files/2024-01/jrc_Breast_cancer_2022_Oct_2023.pdf

3. European Medicines Agency and the European Commission. Biosimilars in the EU: information guide for healthcare
    professionals. European Medicines Agency (EMA). Last Updated October 29, 2019. Accessed April 14, 2026.
    https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf

4. Troein P, Newton M, Stoddart K, Travaglio M, Arias A. The impact of biosimilar competition in Europe. IQVIA; January 2025.
    Accessed April 14, 2026.
    https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2024.pdf

5. Biosimilar medicines: overview. European Medicines Agency (EMA). April 2, 2025. Accessed April 14, 2026.
    https://www.ema.europa.eu/en/human-regulatory-overview/biosimilar-medicines-overview

6. Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta ®(Pertuzumab) and Prolia
    ®/Xgeva ®(Denosumab) Biosimilar Candidates. Organon. June 13, 2022. Accessed April 14, 2026.
    https://www.organon.com/news/organon-enters-into-global-license-agreement-to-commercialize-henlius-investigational-perjeta-pertuzumab-and-prolia-xgeva-
    denosumab-biosimilar-candidates/

 

Cognizant to Acquire Astreya, Deepening Its AI-First Managed Services Capabilities at Scale

  • Acquisition will expand Cognizant’s AI builder technology stack with production-grade AI operations capabilities

  • Astreya, a specialist in AI infrastructure and data center services with deep expertise in data center and managed workplace services, to join Cognizant amid the largest data center infrastructure buildout in history

TEANECK, N.J., April 29, 2026  /PRNewswire/ — Cognizant (Nasdaq: CTSH) today announced that it has entered into a definitive agreement to acquire Astreya, a leading platform-led, global AI-first IT managed services and solutions provider headquartered in San Jose, California, for an undisclosed sum. The transaction is expected to advance Cognizant’s transformation as an AI builder and to meaningfully expand Cognizant’s AI infrastructure foundation capabilities by harnessing Astreya’s extensive managed services capabilities for enterprise clients at scale.

Founded in 2001 and operating across more than thirty-five countries, Astreya brings a 25-year track record as a trusted partner to the world’s largest technology companies, including long-term, outcome-based managed services relationships with six of the “Magnificent Seven” hyperscalers. Its proprietary AI OpsHub platform, with modules for readiness assessment, signal intelligence, analytics, and agentic automation and Tech Innovation Office are expected to deepen Cognizant’s AI talent pool and strengthen its production-grade AI delivery capabilities, translating broad AI potential into specific business outcomes and enterprise-ready platforms tailored to individual client contexts. Combined with Cognizant’s hybrid-by-design AI infrastructure strategy, Astreya’s differentiated expertise in designing, building, and managing AI infrastructure across the full value chain is expected to help support and accelerate customers’ transformation journeys. Astreya’s bespoke client AI solutions and its ecosystem partnerships anchored by Google Cloud Platform and ServiceNow will become key assets within Cognizant’s global delivery infrastructure.

“Between 2025 and 2030 there is a projected $6.7 trillion AI data center infrastructure buildout currently reshaping the global technology landscape, with global capacity expected to double in five years. The five largest hyperscalers are expected to spend nearly $700 billion on infrastructure in 2026 alone. By acquiring Astreya and its proprietary AI tooling and production-grade infrastructure platform, which is complementary to Cognizant’s AI builder stack, we will be even better-positioned to help clients architect their platform-led AI systems and operationalize them at scale,” said Cognizant CEO Ravi Kumar S.

Surya Gummadi, President of Cognizant Americas added, “AI data center investment is a critical path for future economic and job growth, especially in the U.S., where data centers and related high-tech investment activities were estimated to account for 80% of private domestic demand growth in the first half of 2025, and hyperscaler capital spending is now nearing $400 billion annually, with each direct data center job supporting more than six jobs elsewhere in the economy. Effective and credible scaling of AI infrastructure, including data centers, requires deep context and AI builder expertise. We expect the acquisition of Astreya will meaningfully expand Cognizant’s AI Infrastructure capabilities and enhance our powerful ‘Magnificent Seven’ hyperscaler relationships.”

Astreya’s AI OpsHub, with modules for readiness assessment, signal intelligence, analytics, and agentic automation, gives Cognizant a ready-built operations engine already generating measurable results. In addition to the Tech Innovation Office, Astreya’s bespoke client AI solutions, extensive managed services capabilities and its ecosystem partnerships anchored by Google Cloud Platform and ServiceNow will become key assets within Cognizant’s global delivery infrastructure.

“Astreya has redefined what it means to be a trusted partner in the AI era, embedding intelligence into every solution, without losing the human connection that drives real results. Joining Cognizant is the natural next chapter for the Astreya global team and importantly, the clients who have trusted us to operate their most critical technology environments. We have spent the last several years making deliberate, disciplined investments in AI: building platforms, training specialists and fundamentally redesigning how managed services are delivered. We look forward to attacking the AI infrastructure era as a part of Cognizant!” said Romil Bahl, President and CEO, Astreya. 

The acquisition directly accelerates Cognizant’s transition into an AI builder, where the company is helping enterprises bridge the gap between AI infrastructure investment and business value by operationalizing and deploying interdisciplinary talent capable of operating AI systems at scale. Astreya is an operational managed services provider already providing managed services within environments operated by six of the hyperscalers, managing data center infrastructure, AI lab environments, enterprise networks, and workplace technology at hyperscaler scale, with nearly a decade of consecutive outcomes-based managed services delivery.

For Cognizant’s existing clients, the acquisition is expected to deliver proven AI operations capabilities – accelerators, platform IP and hyperscaler-hardened talent – that can be deployed immediately. For Astreya’s existing clients, Cognizant’s global scale and industry breadth is expected to unlock meaningfully expanded service capacity and accelerate the commercialization of emerging Enterprise AI Ops capabilities at a pace not achievable as a standalone managed service provider.

The acquisition is expected to close in the second quarter of 2026, subject to the receipt of required regulatory approvals and other closing conditions. Financial terms were not disclosed.

About Cognizant:
Cognizant (NASDAQ: CTSH) is an AI builder and technology services provider, building the bridge between AI investment and enterprise value by building full-stack AI solutions for our clients. Our deep industry, process and engineering expertise enables us to build an organization’s unique context into technology systems that amplify human potential, realize tangible returns and keep global enterprises ahead in a fast-changing world. See how at www.cognizant.com or @cognizant.

About Astreya:
Astreya is a global IT Managed Services provider that powers enterprises by designing, deploying, and managing complex technology environments. We deliver end-to-end solutions across hybrid cloud, data centers, network infrastructure, and the digital workplace. Intelligent automation and AI run through everything we build to drive efficiency, accelerate service delivery, and clear barriers to growth for our customers.

Advisors
Mayer Brown served as legal advisor to Cognizant. J.P. Morgan Securities LLC served as exclusive financial advisor and Latham & Watkins and Skadden, Arps, Slate, Meagher & Flom LLP served as legal advisors to Astreya.

For more information, contact:

Forward-Looking Statements

This press release includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks, uncertainties and assumptions as to future events that may not prove to be accurate. These statements include, but are not limited to, express or implied forward-looking statements relating to the business of Astreya, including the expected growth; the anticipated benefits of the proposed transaction, including anticipated benefits relating to synergies, new business opportunities, and growth; the expected timing of the transaction closing; the combined company’s plans, objectives, expectations, and intentions; projected AI data center investment; anticipated hyperscaler capital spending; and other statements that are not historical facts. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Factors that could cause actual results to differ materially from those expressed or implied include the risk that the expected benefits from the transaction may not be fully realized or may take longer than anticipated to be realized; disruption to the parties’ businesses as a result of the announcement and pendency of the transaction; the ability to obtain required approvals of the transaction on the timeline expected, or at all, and the risk that such approvals may result in the imposition of conditions that could adversely affect us after the closing of the transaction or adversely affect the expected benefits of the transaction; reputational risk and the reaction of each company’s customers, suppliers, employees or other business partners to the transaction; the failure of the closing conditions in the transaction agreement to be satisfied, or any unexpected delay in closing the transaction or the occurrence of any event, change or other circumstances that could give rise to the termination of the transaction agreement; the possibility that the transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; risks related to management and oversight of the expanded business and operations of Cognizant following the transaction; the risk that combining Astreya’s business and operations into Cognizant will be more costly or difficult than expected, or that we are otherwise unable to successfully integrate Astreya’s businesses with our own, including as a result of unexpected factors or events; and general competitive, economic, political and market conditions and other factors that may affect our future results or that of Astreya, including general economic conditions, the competitive and rapidly changing nature of the markets we compete in, the competitive marketplace for talent and its impact on employee recruitment and retention, our ability to successfully use AI-based technologies, legal, reputational and financial risks resulting from cyberattacks, changes in the regulatory environment, including with respect to immigration and taxes. Additional factors which could affect future results are discussed in our most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Cognizant undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities law.

Appier Advances AI Self-Awareness to Unlock Enterprise ROI

Four research capabilities position Agentic AI as a trustworthy decision partner for enterprises

SINGAPORE, April 29, 2026 /PRNewswire/ — As AI systems become more capable of answering questions and executing tasks, the central question for enterprises has shifted from whether AI can be used to whether it can be trusted. Many AI systems continue to deliver confident responses even when uncertain—an issue that, in business contexts, can escalate from a poor user experience into operational risk.

Appier, an AI-native Agentic AI as a Service (AaaS) company, today announced new research from its global AI team focused on a critical capability: AI self-awareness. The research enables AI to ask more precisely, assess risk, and recognize the limits of its own knowledge. These capabilities are embedded across its Ad Cloud, Personalization Cloud, and Data Cloud—accelerating the transition from usable AI to trustworthy AI, and positioning AI as a reliable decision partner for enterprises.

Enterprise AI risk is no longer hypothetical. From customer service errors to content hallucinations, a consistent pattern has emerged across the industry: AI frequently fails to recognize when it should not respond at all. “As AI agents increasingly connect people, tools, and software into more complex systems, the true source of enterprise advantage will be whether AI can be trusted to make decisions,” said Dr. Chih-Han Yu, Chief Executive Officer and Co-Founder of Appier. “Through our proprietary data, domain expertise, industry-specific models, and frontier research, Appier is bringing trustworthy Agentic AI into real-world business scenarios and enabling enterprises to make decisions alongside AI with confidence.”

Appier has long invested in academic–industry collaboration and frontier research, publishing over 400 papers in leading international journals and conferences. Its recent work on trustworthy Agentic AI has been recognized at top-tier venues including NeurIPS, ACL, and EMNLP.

Appier has identified four key barriers to enterprise AI adoption: Models lose previously learned capabilities after fine-tuning, AI either guesses without sufficient information, or asks too many clarifying questions when faced with ambiguity. Systems lack the risk awareness required to determine when to respond. Traditional benchmarks fail to measure whether AI can actually solve a given task.

To address these challenges, Appier has developed four corresponding capabilities that enable AI to ask precisely, evaluate risk, retain prior knowledge, and accurately assess its own limits.

For precise inquiry, Appier’s research found that internal model judgment alone is insufficient. By incorporating verifiable external feedback and cross-model validation prior to responding, AI can ask more relevant questions and improve the balance between task accuracy and user experience by over 30%.

For risk assessment, Appier applies a “skill decomposition” approach that separates problem-solving, confidence estimation, and expected-value decision-making—allowing AI to act more rationally under uncertainty and reduce high-risk expected loss by 60–70%.

For capability calibration, Appier has introduced a novel mechanism that predicts the probability of a correct answer before responding, providing clearer visibility into capability boundaries at near-zero inference cost (less than one token).

To address catastrophic forgetting, Appier developed a fine-tuning method that identifies and avoids high-perplexity tokens, preserving prior reasoning and instruction-following abilities. This approach reduces performance degradation on non-target tasks to near zero, with a preprocessing time of approximately eight minutes—enabling more stable and efficient deployment in enterprise environments.

These research advances are already integrated into Appier’s AI Agent workflows. In consumer-facing scenarios, a beauty brand’s AI agent without self-awareness might respond to a Mother’s Day restaurant inquiry with off-brand content, fabricate product details, or over-promote its offerings—damaging brand trust.

By contrast, Appier’s Sales and Service Agents understand their boundaries, decline to answer beyond their expertise, clarify ambiguous queries before responding, and recommend products only when appropriate, reducing the risk of misinformation and inappropriate interactions.

The same principle applies in enterprise operations. When a marketer requests an audience of over 100,000 users spanning five years for a Mother’s Day campaign — but the system has access to only one year of data — Appier’s Audience Agent does not fabricate a response. Instead, it flags the data limitation, clarifies the requirement, and proposes viable alternatives with a clear explanation of the trade-offs, reducing operational decision risk. In current deployments, Appier AI Agents block 80%[1] of risky responses for enterprise users, with performance continuing to improve as data evolves.

The future of enterprise AI will be defined not by capability alone, but by trust. As AI evolves from a tool into an “AI colleague,” enterprises require agents that know when to answer, when to ask, and when to decline. By integrating research, technology, and product innovation, Appier is closing this critical gap—transforming AI into a trustworthy partner that delivers measurable, sustainable business outcomes.

About Appier

Appier (TSE: 4180) is an AI-native Agentic AI as a Service (AaaS) company that empowers business decision-making with cutting-edge AdTech and MarTech solutions. Founded in 2012 with the vision of “Making AI Easy by making software intelligent,” Appier endeavors to help businesses turn AI into ROI with its Ad Cloud, Personalization Cloud, and Data Cloud solutions. Now Appier has 17 offices across APAC, the US and EMEA, and is listed on the Tokyo Stock Exchange. Visit www.appier.com for more company information, and visit ir.appier.com/en/ for more IR information.

[1] The 80% benchmark is configurable with each customer. Higher thresholds are achievable but typically require more model usage and cost, balancing risk tolerance with efficiency

CONTACT: pr@appier.com

 

Bybit Launches “Master Trader’s Showtime: TradFi vs Crypto” Tournament With 200,000 USDT Prize Pool

DUBAI, UAE, April 29, 2026 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, has announced the launch of its “Master Trader’s Showtime: TradFi vs Crypto,” a multi-round global trading competition designed to highlight performance across traditional finance and cryptocurrency strategies, with a total prize pool of 200,000 USDT.

The competition will take place over two independent rounds. Round 1 is active now and will run until May 13, 2026, at 10:00 UTC, followed by Round 2 from May 18, 2026, at 10:00 UTC to June 2, 2026, at 10:00 UTC. Each round will feature its own leaderboard and prize pool of 100,000 USDT.

Participants will compete as Master Traders on Bybit Copy Trading, selecting either a Classic or TradFi trading category at registration. Rankings will be determined by a combination of total team trading volume and profit and loss performance, factoring in both Master Traders and their Followers. Followers are automatically enrolled upon copying a registered Master Trader.

To qualify for leaderboard placement, participants must meet minimum trading volume thresholds. Classic traders are required to reach at least 75,000 USDT in total Copy Trading volume, while TradFi participants must achieve at least 1,500,000 USDx. Each Master Trader must also maintain a minimum of 20 active Followers.

The competition will reward the top 50 Master Traders in each round. The first-place team will receive 25,000 USDT, followed by 12,000 USDT for second place and 8,000 USDT for third. Additional rewards will be distributed across lower-ranked positions, with payouts shared between Master Traders and their Followers. Master Traders receive 50 percent of total rewards, while the remaining portion is distributed proportionally among Followers based on trading volume.

In addition to leaderboard rewards, the event includes engagement-based incentives. During the first week of each round, users may allocate “likes” to Master Traders. If a liked trader finishes within the top three, eligible participants may share in a 1,000 USDT reward pool. Additional boosted rewards are available for users who both like and continue copying a Master Trader throughout the round.

Leaderboard standings will be updated daily on a T+1 basis, with final rankings verified following internal compliance and data reviews. Rewards will be distributed as USDT airdrops to eligible participants within 14 working days after the conclusion of each round.

Participation is subject to eligibility requirements, including identity verification and geographic restrictions. The event is not available to users residing in the European Economic Area. Institutional users and market makers are also excluded.

The tournament is designed to encourage competitive trading while reinforcing transparency and fairness across its Copy Trading ecosystem.

#Bybit / #NewFinancialPlatform

Bybit Launches “Master Trader’s Showtime: TradFi vs Crypto” Tournament With 200,000 USDT Prize Pool
Bybit Launches “Master Trader’s Showtime: TradFi vs Crypto” Tournament With 200,000 USDT Prize Pool

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

iQIYI Launches Variety Show “Voices of Youth”, Putting China’s First Pop Performance Choral Show on a Global Stage

BEIJING, April 29, 2026 /PRNewswire/ — On April 24, iQIYI, China’s leading online entertainment platform, launched “Voices of Youth”, a brand-new variety show bringing together 25 young artists spanning vocalists, idol artists, crossover actors, and emerging musicians to form China’s first pop performance choral show. Before its premiere, the show topped the Most Anticipated Variety Shows chart on Weibo, China’s leading social media platform, multiple times and debuted simultaneously on iQIYI International across markets to strong reception.

“Voices of Youth” introduces a first-of-its-kind “pop performance choral” format, moving beyond both traditional choral conventions and domestic idol competition shows. Integrating SATB (Soprano, Alto, Tenor, Bass) four-part professional choral arrangements with dance and theatrical staging, the show uses mixed-voice ensembles to enrich the musical texture and elevate the visual impact, delivering an immersive audiovisual experience that bridges choral artistry and popular culture. Grounded in the creative energy of today’s Chinese youth, the format speaks a musical language familiar to international audiences.

The show follows 25 young artists through intensive training, competitive stage performance, and international cultural exchange, chronicling their journey from strangers into a unified ensemble and capturing the passion and camaraderie that define the experience of youth.

In its song selection and arrangements, the show is closely attuned to the aesthetic preferences of younger audiences, bringing choral music out of the concert hall and into the mainstream. The production team applies a world-class choral training framework across varieties of full-scale stage productions this season, holding every performance to rigorous artistic standards. Beyond the stage, the show serves as a platform for international cultural exchange, bringing together leading choral ensembles from China and abroad to showcase the musical talent and spirit of today’s Chinese youth, and to build genuine connections between young artists across cultures.

“Voices of Youth” is the latest example of iQIYI’s investment in original variety show, developing new formats that go beyond existing IP. By pairing a universally accessible art form, the series is part of iQIYI’s broader effort to bring Chinese creative talent to a global audience.

CONTACT: iQIYI Press
press@qiyi.com

INTCO Medical Reports 2025 Results with Resilient Growth, Revenue Reaches Four-Year High as Industry Rebalances

ZIBO, China, April 29, 2026 /PRNewswire/ — INTCO Medical (“INTCO” or “the Company”), a leading global manufacturer of disposable gloves, reported its 2025 annual results, with revenue reaching RMB 9.93 billion (approximately US$1.46 billion), up 4.23% year over year and marking a four-year high.

The company’s annualized production capacity for disposable non-latex gloves reached 103 billion pieces, including 70 billion nitrile gloves, placing INTCO among the world’s largest disposable glove manufacturers by production capacity and a top global nitrile glove manufacturer.

Intco Medical Business Segments: Medical Consumables, Rehabilitation Medical Equipment and Physical Therapy
Intco Medical Business Segments: Medical Consumables, Rehabilitation Medical Equipment and Physical Therapy

During the reporting period, INTCO maintained stable operations amid industry rebalancing. Net profit attributable to shareholders reached RMB 1.01 billion (approximately US$148.03 million), while total assets exceeded RMB 40 billion (approximately US$5.86 billion), up 15.77% year over year. Gross margin rose 0.48 percentage points to 24.12%, and net cash flow from operating activities increased 74.69% to RMB 1.89 billion (approximately US$277.00 million), supporting the company’s global expansion and long-term growth.

Scale and Manufacturing Capabilities Strengthen Core Business

Disposable gloves remained INTCO Medical’s core business. As of the end of 2025, the company operated 10 R&D and manufacturing bases worldwide, with annualized capacity for disposable non-latex gloves reaching 103 billion pieces, including 70 billion nitrile gloves and 33 billion vinyl gloves.

The company continued to enhance its automated production systems, self-developed production lines and precision DCS systems to improve production efficiency, energy utilization and product quality. Its production scale remained among the industry’s largest, with product yield continuing to stay above 99%.

With a global development strategy, INTCO Medical expanded overseas production capacity, including new facilities in Vietnam, strengthening supply chain resilience, supporting stable delivery and enhancing responsiveness to regional demand.

Beyond its core glove business, INTCO expanded its healthcare and personal protection portfolio, with rehabilitation medical equipment and physical therapy businesses growing and supporting a more balanced revenue mix.

Global Reach, Innovation and Digitalization Support Long-Term Growth

Investment in innovation remained a key strategic priority. In 2025, research and development spending reached RMB 404 million (approximately US$59.21 million), representing 4.07% of revenue and significantly above the industry average, reflecting the company’s continued commitment to innovation.

The company continued to advance new materials, automation technologies, and product development, including the launch of innovative products such as Syntex™ Synthetic Disposable Latex Gloves and Synmax Pro Exam Gloves. Total patent holdings continued to grow, strengthening long-term competitive barriers.

INTCO continued to deepen its global market network, serving more than 15,000 customers across more than 150 countries and regions. Supported by a global marketing team of nearly 500 professionals, the company has established marketing and service centers in the U.S., Canada, Germany, Japan, Malaysia, Singapore and Hong Kong SAR, China, with plans to further expand in the Middle East, South America and Oceania to better support local customers.

INTCO is integrating digital technologies and AI across its operations, using data platforms and AI-driven tools to improve efficiency, decision-making and internal capabilities. The company continued to advance its ESG practices, including wind and solar projects that generated 12,537.23 MWh of clean energy in 2025, supporting sustainable development.

Looking ahead, INTCO will leverage its scale, technology and global network to strengthen its healthcare supply chain, improve efficiency, expand overseas capacity and accelerate product innovation.

About INTCO Medical

INTCO Medical is a leading global manufacturer of disposable gloves. As a high-tech manufacturing company, INTCO specializes in the R&D, production and marketing of medical consumables and durable medical equipment. The company’s core business segments include medical consumables, rehabilitation medical equipment and physical therapy. For more information, please visit https://www.intcomedical.com/.

State Grid Changzhou Power Pioneers Drone-Based Ultraviolet Imaging Technology for Precision Power Line Fault Detection

CHANGZHOU, China, April 29, 2026 /PRNewswire/ — State Grid Changzhou Power Supply Company has deployed drone-based ultraviolet (UV) imaging technology for the first time to enable precision inspection of distribution lines in Liyang, Changzhou. The new technical solution supports early detection, accurate evaluation and timely disposal of hidden line defects, strengthening the reliability and operational safety of the local power grid.

Equipped with a professional UV imager, a DJI M350 drone executed automatic, high-precision scanning of key power facilities such as line insulators and wire connectors via preset flight routes. Distinct from conventional inspection approaches, UV imaging can sensitively capture ultraviolet signals triggered by electrical anomalies and identify subtle corona discharge defects invisible to the human eye. As a critical early warning sign of equipment failure, corona discharge can be detected in advance, enabling targeted troubleshooting and proactive risk prevention.

This smart inspection method allows maintenance teams to pinpoint faults remotely without pole climbing or close access to live equipment. It effectively boosts inspection efficiency and accuracy while eliminating safety hazards from high-altitude live-line operations, substantially elevating the overall safety and intelligence level of grid maintenance.

The adoption of drone UV imaging technology represents a key step in State Grid Changzhou Power’s digital and intelligent upgrade of grid operation and maintenance. Centering on technology-enabled smart grid management, the company has advanced drone inspection from manual operation to autonomous cruising and established a comprehensive air-ground-space integrated inspection system.

Furthermore, the company has launched an intelligent early warning system powered by more than 10,000 high-definition monitoring devices, realizing round-the-clock real-time monitoring of line operating status and forming a standardized closed-loop mechanism for defect identification, assessment and rectification. With continuous technological innovation and refined management, State Grid Changzhou Power delivers stable, high-quality power supply, underpinning the secure operation of the regional power grid and sustaining local high-quality economic and social development.